- Home
- NXTC vs PLUR Comparison
NXTC vs PLUR Comparison
Compare NXTC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- PLUR
- Stock Information
- Founded
- NXTC 2015
- PLUR 2001
- Country
- NXTC United States
- PLUR Israel
- Employees
- NXTC N/A
- PLUR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXTC Health Care
- PLUR Health Care
- Exchange
- NXTC Nasdaq
- PLUR Nasdaq
- Market Cap
- NXTC 31.6M
- PLUR 27.7M
- IPO Year
- NXTC 2019
- PLUR N/A
- Fundamental
- Price
- NXTC $0.89
- PLUR $4.27
- Analyst Decision
- NXTC Strong Buy
- PLUR
- Analyst Count
- NXTC 2
- PLUR 0
- Target Price
- NXTC $4.00
- PLUR N/A
- AVG Volume (30 Days)
- NXTC 218.5K
- PLUR 28.5K
- Earning Date
- NXTC 11-07-2024
- PLUR 02-10-2025
- Dividend Yield
- NXTC N/A
- PLUR N/A
- EPS Growth
- NXTC N/A
- PLUR N/A
- EPS
- NXTC N/A
- PLUR N/A
- Revenue
- NXTC N/A
- PLUR $598,000.00
- Revenue This Year
- NXTC N/A
- PLUR N/A
- Revenue Next Year
- NXTC N/A
- PLUR N/A
- P/E Ratio
- NXTC N/A
- PLUR N/A
- Revenue Growth
- NXTC N/A
- PLUR 135.43
- 52 Week Low
- NXTC $0.87
- PLUR $3.76
- 52 Week High
- NXTC $2.57
- PLUR $8.48
- Technical
- Relative Strength Index (RSI)
- NXTC 22.88
- PLUR 37.44
- Support Level
- NXTC $1.06
- PLUR $4.73
- Resistance Level
- NXTC $1.21
- PLUR $5.45
- Average True Range (ATR)
- NXTC 0.10
- PLUR 0.29
- MACD
- NXTC -0.02
- PLUR -0.10
- Stochastic Oscillator
- NXTC 5.21
- PLUR 0.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.